Pre-made Cantuzumab Mertansine benchmark antibody (Whole mAb ADC, anti-MUC1 therapeutic antibody, Anti-ADMCKD/ADMCKD1/ADTKD2/CA 15-3/CD227/Ca15-3/EMA/H23AG/KL-6/MAM6/MCD/MCKD/MCKD1/SEC/X/ZD/PEM/PEMT/PUM Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-INN-769

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-INN-769 Category Tag

Product Details

Pre-made Cantuzumab Mertansine benchmark antibody (Whole mAb ADC, anti-MUC1 therapeutic antibody, Anti-ADMCKD/ADMCKD1/ADTKD2/CA 15-3/CD227/Ca15-3/EMA/H23AG/KL-6/MAM6/MCD/MCKD/MCKD1/SEC/X/ZD/PEM/PEMT/PUM Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cantuzumab mertansine (SB-4875; huC242-DM1) is an antibody-drug conjugate investigated to treat colorectal cancer and other types of cancer.[1] It is a humanized monoclonal antibody, cantuzumab (huC242) linked to a cytotoxic agent, mertansine (DM1).[2] It was developed by ImmunoGen.

Products Name (INN Index)

Pre-Made Cantuzumab Mertansine Biosimilar, Whole Mab Adc, Anti-Muc1 Antibody: Anti-ADMCKD/ADMCKD1/ADTKD2/CA 15-3/CD227/Ca15-3/EMA/H23AG/KL-6/MAM6/MCD/MCKD/MCKD1/SEC/X/ZD/PEM/PEMT/PUM therapeutic anti

INN Name

cantuzumab mertansine

Target

MUC1

Format

Whole mAb ADC

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

IgG1 – kappa

VD LC

IgG1 – kappa

Highest_Clin_Trial (Jan '20)

NA

Est. Status

NA

100% SI Structure

NA

99% SI Structure

NA

95-98% SI Structure

NA

Year Proposed

NA

Companies

GlaxoSmithKline (Brentford UK) / ImmunoGen?Inc. (Cambridge MA USA)

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

MUC1

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide